Semaglutide (Wegovy) trial to evaluate efficacy for methamphetamine use disorder
Background
Methamphetamine use disorder (MeUD) represents a significant public health challenge, characterized by high rates of relapse and severe health consequences. Currently, there are no FDA-approved pharmacotherapies specifically for MeUD, leaving a critical gap in treatment options. Existing behavioral interventions, while helpful, often struggle with adherence and sustained abstinence. Repurposing drugs with known safety profiles and potential mechanisms of action, such as semaglutide, a GLP-1R agonist, offers a promising avenue. GLP-1R activation has shown potential in modulating reward pathways and reducing craving in other substance use disorders, suggesting a novel approach to MeUD.
Study Design
This two-phase study, named GEM (Glutide for Ending Methamphetamine), is designed to evaluate semaglutide (Wegovy) for methamphetamine use disorder (MeUD). Phase 1 is an open-label, single-arm pilot study enrolling 25 participants. These participants will receive Wegovy over a 12-week treatment period, followed by a week 20 follow-up. This initial phase will assess feasibility, acceptability, and preliminary efficacy. Phase 2 will be a Phase IIb randomized-controlled trial (RCT) enrolling 162 participants across two sites. This phase will randomize participants to either Wegovy or placebo, with blinding of group assignment, to determine definitive efficacy.
Results
As a 'NOT_YET_RECRUITING' study, no findings are available yet. However, the study is designed to generate crucial data on the potential of semaglutide for methamphetamine use disorder (MeUD). The initial pilot phase, involving 25 participants, aims to establish the practical feasibility and patient acceptability of Wegovy as a treatment. It will also provide preliminary insights into its efficacy, which will inform the larger, more definitive Phase IIb trial. The primary objective of the Phase IIb trial, enrolling 162 participants, is to rigorously determine the efficacy of Wegovy compared to placebo in treating MeUD. This will involve assessing outcomes related to methamphetamine use reduction and abstinence. The study is projected to complete by February 2030, with results expected after this period. The design specifically targets the evaluation of a GLP-1R agonist's impact on addiction pathways.
Key Findings
- Pilot phase will evaluate feasibility of Wegovy for MeUD in 25 participants.
- Pilot phase will assess acceptability of Wegovy in MeUD participants over 12 weeks.
- Pilot phase will determine preliminary efficacy of Wegovy for MeUD.
- Phase IIb RCT will establish efficacy of Wegovy vs. placebo in 162 participants for MeUD.
Why It Matters
If successful, this trial could represent a significant breakthrough, offering the first FDA-approved pharmacotherapy for methamphetamine use disorder (MeUD). A positive outcome would provide clinicians with a much-needed tool to combat this devastating addiction, potentially improving patient outcomes and reducing public health burden. For individuals struggling with MeUD, semaglutide could offer a novel, accessible treatment option, potentially reducing cravings and relapse rates. While the study is in its early stages (not yet recruiting), its design as a Phase IIb RCT indicates a serious commitment to clinical translation. If efficacy is demonstrated, further large-scale Phase III trials would be the next step, bringing it closer to a usable protocol for widespread clinical application. This research also expands the understanding of GLP-1R agonists beyond metabolic disorders into the realm of addiction medicine.
semaglutide
wegovy
methamphetamine-use-disorder
meud
addiction
clinical-trial